Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +51.97%
#2 PondCoin PondCoin +49.80%
#3 Pons Pons +44.46%
#4 TENDIES TENDIES +38.89%
#5 StonkBroker StonkBroker +34.93%
#6 Purr Purr +30.18%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.85%
#8 Ocean Protocol Ocean Protocol +29.26%
#9 Magma Finance Magma Finance +29.13%
#10 SkyAI SkyAI +26.83%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Classificação em ações #28895
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Preço da ação
$0.0573
Valor de mercado
$24.08M
Variação (1 dia)
0.53%
Variação (1 ano)
-28.55%
País
US
Negociar Provectus Biopharmaceuticals, Inc. (PVCT)

Categoria

Healthcare
Histórico de preços das ações de Provectus Biopharmaceuticals, Inc. (PVCT)
Preço de fecho mais alto: $0.06 em 2026-08-01

Preço de fecho mais baixo: $1.50K em 1997-01-01
Histórico de preços das ações da Provectus Biopharmaceuticals, Inc. de 1997 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 4.90%
2025 -49.43%
2024 14.98%
2023 -8.24%
2022 129.37%
2021 -13.91%
2020 -4.11%
2019 6.20%
2018 9.56%
2017 254.83%
2016 -96.41%
2015 -50.33%
2014 -42.52%
2013 161.88%
2012 -24.41%
2011 -19.14%
2010 2.53%
2009 -1.05%
2008 -53.93%
2007 68.37%
2006 27.17%
2005 62.37%
2004 -51.83%
2003 269.90%
2002 -99.95%
2001 3.10%
2000 -61.25%
1999 0.00%
1998 0.00%
1997 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $552.07 41.28%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $168.77 504.69%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 57.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $117.42 -19.34%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $753.28 8.59%
CH